Targeting TMEM16A-encoded Ca2+-activated Cl− channels: a new paradigm for antihypertensive therapy?

A small molecule inhibitor of the chloride channel TMEM16A blocks vascular smooth muscle contraction and lowers blood pressure in spontaneously hypertensive rats

(2021) Onur Cil et al.   KIDNEY INTERNATIONAL

Antihypertensive Agents in Older Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

(2019) Mohammad Hassan Murad et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic PAH

(2019) Rita Papp et al.   EUROPEAN RESPIRATORY JOURNAL

Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50 (ED50)

(2019) Simon B. Dimmitt et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association

(2018) Emelia J. Benjamin et al.   CIRCULATION

Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A)

(2017) Eric C. Truong et al.   JOURNAL OF MEDICINAL CHEMISTRY

Molecular and Functional Significance of Ca2+-Activated Cl− Channels in Pulmonary Arterial Smooth Muscle

(2015) Normand Leblanc et al.   Pulmonary Circulation

Disruption of vascular Ca2+-activated chloride currents lowers blood pressure

(2014) Christoph Heinze et al.   JOURNAL OF CLINICAL INVESTIGATION

Downregulation of TMEM16A Calcium-Activated Chloride Channel Contributes to Cerebrovascular Remodeling During Hypertension by Promoting Basilar Smooth Muscle Cell Proliferation

(2012) Mi Wang et al.   CIRCULATION